Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
03 2020
Historique:
received: 29 05 2019
accepted: 21 10 2019
pubmed: 29 12 2019
medline: 15 12 2020
entrez: 29 12 2019
Statut: ppublish

Résumé

We sought to confirm a bidirectional association between severe hypoglycemic events (SHEs) and cardiovascular (CV) event risk and to characterize individuals at dual risk. In a post hoc analysis of 14,752 Exenatide Study of Cardiovascular Event Lowering (EXSCEL) participants, we examined time-dependent associations between SHEs and subsequent major adverse cardiac events (CV death, nonfatal myocardial infarction [MI] or stroke), fatal/nonfatal MI, fatal/nonfatal stroke, hospitalization for acute coronary syndrome (hACS), hospitalization for heart failure (hHF), and all-cause mortality (ACM), as well as time-dependent associations between nonfatal CV events and subsequent SHEs. SHEs were uncommon and not associated with once-weekly exenatide therapy (hazard ratio 1.13 [95% CI 0.94-1.36], These findings, showing greater risk of SHEs after CV events as well as greater risk of CV events after SHEs, validate a bidirectional relationship between CV events and SHEs in patients with high comorbidity scores.

Identifiants

pubmed: 31882409
pii: dc19-1079
doi: 10.2337/dc19-1079
doi:

Substances chimiques

Hypoglycemic Agents 0
Exenatide 9P1872D4OL

Banques de données

ClinicalTrials.gov
['NCT01144338']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

643-652

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 by the American Diabetes Association.

Auteurs

Eberhard Standl (E)

Munich Diabetes Research Group e.V. at Helmholtz Centre, Neuherberg, Germany eberhard.standl@lrz.uni-muenchen.de.

Susanna R Stevens (SR)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Yuliya Lokhnygina (Y)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

M Angelyn Bethel (MA)

Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K.

John B Buse (JB)

University of North Carolina School of Medicine, Chapel Hill, NC.

Stephanie M Gustavson (SM)

AstraZeneca Research and Development, Gaithersburg, MD.

Aldo P Maggioni (AP)

ANMCO Research Center, Florence, Italy.

Robert J Mentz (RJ)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Adrian F Hernandez (AF)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH